Neuropathological features of a case with schizophrenia and prion protein gene P102L mutation before onset of Gerstmann-Sträussler-Scheinker disease

Kensuke Sasaki, Katsumi Doh-Ura, Akiko Furuta, Sachi Nakashima, Yumi Morisada, Jun Tateishi, Toru Iwaki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gerstmann-Sträussler-Schein ker disease (GSS) is a hereditary transmissible spongiform encephalopathy associated with prion protein gene mutation P102L. The age of onset is roughly restricted to around the sixth decade; however, it is unclear whether the disease-specific pathology of GSS is already evident in the pre-clinical stage. We had a chance to examine an autopsy case with PRNP P102L mutation. The patient had died at 50 years of age before the clinical symptoms of GSS had appeared; neither neuronal loss, gliosis nor spongiform change was found anywhere in the brain. Immunohistochemistry failed to detect any deposition of prion protein. It is thus considered that amyloid plaque formation in GSS probably develops in a relatively rapid fashion compared with Alzheimer's disease. Although the patient suffered from schizophrenia, no significant pathological changes were detected except for astrocytic inclusion bodies in the cerebral cortex. The nature and significance of the inclusion bodies, which are not observed in patients with GSS, remain unclear.

Original languageEnglish
Pages (from-to)92-96
Number of pages5
JournalActa Neuropathologica
Volume106
Issue number1
Publication statusPublished - Jul 1 2003

Fingerprint

Schizophrenia
Inclusion Bodies
Mutation
Genes
Prion Diseases
Gliosis
Amyloid Plaques
Age of Onset
Cerebral Cortex
Autopsy
Alzheimer Disease
Immunohistochemistry
Pathology
Brain
Prion Proteins

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Neuropathological features of a case with schizophrenia and prion protein gene P102L mutation before onset of Gerstmann-Sträussler-Scheinker disease. / Sasaki, Kensuke; Doh-Ura, Katsumi; Furuta, Akiko; Nakashima, Sachi; Morisada, Yumi; Tateishi, Jun; Iwaki, Toru.

In: Acta Neuropathologica, Vol. 106, No. 1, 01.07.2003, p. 92-96.

Research output: Contribution to journalArticle

Sasaki, Kensuke ; Doh-Ura, Katsumi ; Furuta, Akiko ; Nakashima, Sachi ; Morisada, Yumi ; Tateishi, Jun ; Iwaki, Toru. / Neuropathological features of a case with schizophrenia and prion protein gene P102L mutation before onset of Gerstmann-Sträussler-Scheinker disease. In: Acta Neuropathologica. 2003 ; Vol. 106, No. 1. pp. 92-96.
@article{151fe71041f24834ba790cc9ab44a364,
title = "Neuropathological features of a case with schizophrenia and prion protein gene P102L mutation before onset of Gerstmann-Str{\"a}ussler-Scheinker disease",
abstract = "Gerstmann-Str{\"a}ussler-Schein ker disease (GSS) is a hereditary transmissible spongiform encephalopathy associated with prion protein gene mutation P102L. The age of onset is roughly restricted to around the sixth decade; however, it is unclear whether the disease-specific pathology of GSS is already evident in the pre-clinical stage. We had a chance to examine an autopsy case with PRNP P102L mutation. The patient had died at 50 years of age before the clinical symptoms of GSS had appeared; neither neuronal loss, gliosis nor spongiform change was found anywhere in the brain. Immunohistochemistry failed to detect any deposition of prion protein. It is thus considered that amyloid plaque formation in GSS probably develops in a relatively rapid fashion compared with Alzheimer's disease. Although the patient suffered from schizophrenia, no significant pathological changes were detected except for astrocytic inclusion bodies in the cerebral cortex. The nature and significance of the inclusion bodies, which are not observed in patients with GSS, remain unclear.",
author = "Kensuke Sasaki and Katsumi Doh-Ura and Akiko Furuta and Sachi Nakashima and Yumi Morisada and Jun Tateishi and Toru Iwaki",
year = "2003",
month = "7",
day = "1",
language = "English",
volume = "106",
pages = "92--96",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Neuropathological features of a case with schizophrenia and prion protein gene P102L mutation before onset of Gerstmann-Sträussler-Scheinker disease

AU - Sasaki, Kensuke

AU - Doh-Ura, Katsumi

AU - Furuta, Akiko

AU - Nakashima, Sachi

AU - Morisada, Yumi

AU - Tateishi, Jun

AU - Iwaki, Toru

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Gerstmann-Sträussler-Schein ker disease (GSS) is a hereditary transmissible spongiform encephalopathy associated with prion protein gene mutation P102L. The age of onset is roughly restricted to around the sixth decade; however, it is unclear whether the disease-specific pathology of GSS is already evident in the pre-clinical stage. We had a chance to examine an autopsy case with PRNP P102L mutation. The patient had died at 50 years of age before the clinical symptoms of GSS had appeared; neither neuronal loss, gliosis nor spongiform change was found anywhere in the brain. Immunohistochemistry failed to detect any deposition of prion protein. It is thus considered that amyloid plaque formation in GSS probably develops in a relatively rapid fashion compared with Alzheimer's disease. Although the patient suffered from schizophrenia, no significant pathological changes were detected except for astrocytic inclusion bodies in the cerebral cortex. The nature and significance of the inclusion bodies, which are not observed in patients with GSS, remain unclear.

AB - Gerstmann-Sträussler-Schein ker disease (GSS) is a hereditary transmissible spongiform encephalopathy associated with prion protein gene mutation P102L. The age of onset is roughly restricted to around the sixth decade; however, it is unclear whether the disease-specific pathology of GSS is already evident in the pre-clinical stage. We had a chance to examine an autopsy case with PRNP P102L mutation. The patient had died at 50 years of age before the clinical symptoms of GSS had appeared; neither neuronal loss, gliosis nor spongiform change was found anywhere in the brain. Immunohistochemistry failed to detect any deposition of prion protein. It is thus considered that amyloid plaque formation in GSS probably develops in a relatively rapid fashion compared with Alzheimer's disease. Although the patient suffered from schizophrenia, no significant pathological changes were detected except for astrocytic inclusion bodies in the cerebral cortex. The nature and significance of the inclusion bodies, which are not observed in patients with GSS, remain unclear.

UR - http://www.scopus.com/inward/record.url?scp=0038082169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038082169&partnerID=8YFLogxK

M3 - Article

VL - 106

SP - 92

EP - 96

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 1

ER -